MDM2 and neoplasm: Nutlin‐3, which inhibits the interaction between p53 and its negative regulator MDM2 by blocking the p53‐binding domain of MDM2, has been exploited to remove healthy fragments from TP53‐mutant tumour organoids.9, 13